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Abstract Desethylamiodarone (DEA) acts as a competitive
inhibitor of triiodothyronine (T3) binding to the K1-thyroid
hormone receptor (TRK1) but as a non-competitive inhibitor with
respect to TRL1. To gain insight into the position of the binding
site of desethylamiodarone on TRL1 we investigated the naturally
occurring mutants Y321C, R429Q, P453A, P453T and the
artificial mutants L421R and E457A in the ligand binding
domain of human TRL1. The IC50 values (in WM) of DEA for
P453A (50 þ 11) and P453T (55 þ 16) mutant TRL1 are not
different from that for the wild type TRL1 (56 þ 15), but the IC50
values of R429Q (32 þ 7; P6 0.001) and E457A (17 þ 3;
P6 0.001) are significantly lower than of the wild type.
Scatchard plots and Langmuir analyses indicate a non-compet-
itive nature of the inhibition by DEA of T3 binding to all four
mutant TRL1s tested. Mutants P453A and P453T do not
influence overall electrostatic potential, and also do not influence
the affinity for DEA compared to wild type. Mutant E457A
causes a change from a negatively charged amino acid to a
hydrophobic amino acid, enhancing the affinity for DEA. Mutant
R429Q, located in helix 11, causes an electrostatic potential
change from positive to uncharged, also resulting in greater
affinity for DEA. We therefore postulate that amino acids R429
and E457 are at or close to the binding site for DEA, and that
DEA does not bind in the T3 binding pocket itself, in line with the
non-competitive nature of the inhibition of T3 binding to TRL1 by
DEA.
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1. Introduction
Amiodarone, an iodinated benzofuran derivative, is a po-
tent antiarrhythmic and antianginal drug. It also profoundly
a¡ects peripheral thyroid hormone metabolism. The drug
causes a dose-dependent decrease of serum triiodothyronine
(T3) concentrations due to diminished hepatic thyronxine (T4)
5P-deiodination secondary to inhibition of T4 transport across
the plasma membrane [1]. It also decreases gene expression of
thyroid hormone-dependent genes such as K-myosin heavy
chain and the low density lipoprotein receptor [2,3]. The hy-
pothesis that amiodarone is a thyroid hormone antagonist has
been further supported by the ¢nding that desethylamiodar-
one (DEA), the major metabolite of amiodarone, inhibits the
binding of T3 to its nuclear receptor. DEA acts as a compet-
itive antagonist with respect to binding of T3 to the thyroid
hormone receptor isoform K1 (TRK1) but interestingly as a
non-competitive antagonist with respect to the thyroid hor-
mone receptor isoform L1 (TRL1) [4,5]. Further insight into
this antagonistic e¡ect of DEA on T3 receptor binding can be
obtained by evaluating the changes in the molecular constitu-
tion of either the drug or the receptor. We have previously
reported the results of competition studies with amiodarone
analogues: the bulky iodine atoms, the hydrophobicity, the
electric charge and the overall size of the analogues markedly
in£uenced the nature and potency of their inhibition on T3
receptor binding [6]. These studies, however, did not provide
further information on the localization of the DEA binding
site on the receptor. Therefore we studied the e¡ect of natur-
ally occurring and arti¢cial mutations in TRL1 which are
known to decrease T3 a⁄nity (R429Q, P453A and P453T),
hormone-dependent transactivation (E457A), homodimeriza-
tion (R429Q) or heterodimerization (L421R, 9th heptad mu-
tant).
2. Materials and methods
2.1. Chemicals
Non-radioactive 3,5,3P-T3 was obtained from Henning GmbH, Ber-
lin, Germany. [125I]T3 (spec. act. 2200 Ci/mmol) was purchased from
New England Nuclear, Boston, MA, USA. DEA was a kind gift of
Sano¢ Recherche (Montpellier, France). All reagents were of the high-
est grade possible.
2.2. Receptor expression
Receptors were expressed in Escherichia coli as a GST fusion pro-
tein using pGEX-2TK vector (Pharmacia Biotech, Sweden) containing
either wild type human TRL1, naturally occurring mutant human
TRL1 Y321C, R429Q, P453A, P453T, or arti¢cial mutant human
TRL1 L421R and E457A (residues 174^461)[7,8]. The cells were
grown overnight in 2UYT-G medium (yeast extract 10 g/l, tryptone
16 g/l, NaCl 5 g/l and 10% (w/v) glucose) and then diluted 1:10 in pre-
warmed (37‡C) medium until an optical density of 1^1.2 was reached.
After IPTG (isopropyl-L-D-thiogalactoside) 1 mM F.D. was added the
cells were grown for another 1.5 h. Cells were then lysed by soni¢ca-
tion in PBS (2U20 s, 50 W on ice). Each receptor protein preparation
was puri¢ed using glutathione-Sepharose 4B a⁄nity resin (Pharmacia
Biotech, Sweden) according to the manufacturer’s instructions with
the following modi¢cations [9^11]: Triton X-100 was used in a ¢nal
concentration of 0.5%, PBS used as a wash solution contained 2 mM
DTT and 0.2 mM PMSF. The proteins were stored at a high concen-
tration in incubation bu¡er (20 mM Tris-HCl, 0.25 M sucrose, 1 mM
EDTA, 50 mM NaCl, 5% (v/v) glycerol, 5 mM DTT pH 7.6) in liquid
nitrogen, thawed on ice and diluted to the desired concentration just
before use.
2.3. T3 receptor binding assay
The receptor proteins were incubated with [125I]T3 (10311 M) for
30 min at 22‡C in a shaking water bath in incubation bu¡er contain-
ing 0.025% Triton X-100, 0.05% BSA and 1% ethanol (v/v). These
additions to the incubation bu¡er were necessary to solubilize DEA in
a hydrophilic environment as demonstrated previously [5]. Total in-
cubation volume was 0.5 ml. Reactions were stopped by chilling on
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ice-water. Bound and unbound [125I]T3 were separated at 4‡C using a
small Sephadex G25 medium column (bed volume 2 ml, swollen in
incubation bu¡er with 0.05% BSA) in a Pasteur pipette. Four 0.8 ml
fractions, containing the bound hormone fraction, were collected us-
ing incubation bu¡er as eluent. Speci¢c binding was determined by
calculating the di¡erence between the counts bound in the absence
and presence of an excess (1037 M) of non-radioactive T3. All incu-
bations were done in duplicate. The proteins were diluted to provide a
maximal binding capacity (MBC) of the T3 receptor preparations
between 3 and 10U10310 M.
The potency of DEA to inhibit the binding of T3 to the wild type
and the mutated L1-T3 receptors was tested over a concentration
range of 1037 to 1034 M. DEA solubilized as a stock solution of
1032 M in ethanol was incubated in various concentrations with re-
ceptor proteins and [125I]T3 as described above. In all tubes the ¢nal
ethanol concentration was 1% (v/v). From these experiments the IC50
values of DEA for the wild type and the mutated L1-T3 receptors were
calculated.
Scatchard analyses were performed with DEA concentrations
around the IC50 values. Receptor proteins and [125I]T3 were incubated
with increasing amounts of non-radioactive T3 (1U10310 to
33U10310 M) in the absence or presence of DEA. Four to six separate
experiments were done for wild type and mutant receptor proteins; in
each experiment the inhibitory e¡ect of DEA was tested at two or
three concentrations. MBC and Ka values were calculated using the
non-linear curve-¢tting computer program Ligand (Biosoft, Cam-
bridge, UK). Changes in MBC and Ka as a function of DEA concen-
tration were analyzed by two-way ANOVA. Langmuir plots were
prepared from the data of the Scatchard analyses.
3. Results
3.1. Inhibitory potency of DEA for wild type and mutant TRL1
The relative a⁄nities for T3 of all TRL1-GST fusions (wild
type and mutants) are similar to results obtained before [7,8].
The IC50 value of DEA for the wild type human TRL1 is
56 þ 15 WM (Table 1), in good accordance with the ¢gure
reported for rat TRL1 [5]. No reliable IC50 values for the
mutant L1 receptors Y321C and L421R could be determined
because the initial binding of [125I]T3 was too low. The IC50
values of DEA for the mutant receptors P453A and P453T are
similar to those of the wild type, implying that there is no
e¡ect of P435 mutants, which however do in£uence T3 bind-
ing, on DEA binding. The IC50 values for the mutant recep-
tors R429Q and E457A are signi¢cantly lower indicating that
their a⁄nity for DEA is increased compared to wild type
(Table 1, Fig. 1). The inhibitory potency (IC50) of DEA on
T3 binding bears no relation to the a⁄nity (Ka) of the di¡er-
ent mutants for T3 binding (Table 2).
3.2. Nature of inhibition of T3 binding by DEA on wild type
and mutant TRL1
Representative Scatchard plots of the e¡ect of DEA on T3
binding to the di¡erent TRL1s are depicted in Fig. 2. DEA
decreased both MBC and Ka in a dose-dependent manner as
evident from the Scatchard plots for the binding of T3 to the
wild type and the mutant TRL1s (P453A, P453T and E457A)
(Table 2). Langmuir plots demonstrated non-competitive in-
hibition by DEA for the wild type and these three mutated
Table 1
Inhibition of the binding of [125I]T3 to wild type and mutant human
TRL1 by DEA
Human TRL1 Number of experiments IC50 WM
(mean þ S.D.)
Wild type TRL1 8 56 þ 15
Y321C mTRL1 Bo too low to determine IC50
L421R mTRL1 Bo too low to determine IC50
P453A mTRL1 7 50 þ 11
P453T mTRL1 9 55 þ 16
R429Q mTRL1 9 32 þ 7*
E457A mTRL1 4 17 þ 3*
Bo, initial binding.
*P6 0.001 vs. wild type, determined by t-test.
Fig. 1. Binding of T3 to the wild type and human mutant TRL1.
Wild type (a), R429Q (O), P453A (8), P453T (F) and E457A (R)
were incubated with [125 I]T3 in the presence of increasing concen-
trations DEA. Binding is expressed as a percentage of the control
value without DEA. Data are presented as the mean þ S.D.
Table 2
Characteristics of the inhibition of the binding of T3 to the wild type and mutant human L1-T3 receptors by DEA, as evident from Scatchard
plots
DEA ^ 1035 M 2.5U1035 M 5U1035 M P value
MBC 10310 M
Wild type 5.86 þ 1.0 5.21 þ 0.73 4.57 þ 0.66 0.03
R429Q 5.60 þ 0.41 4.57 þ 0.59 2.96 þ 1.00 0.0003
P453A 7.47 þ 1.94 6.34 þ 1.58 5.06 þ 1.82 0.03
P453T 8.82 þ 1.24 8.78 þ 1.22 7.83 þ 1.23 6.32 þ 2.39 0.007
E457A 3.96 þ .38 2.94 þ 0.16 1.62 þ 0.30 0.002
Ka 109 l/M
Wild type 1.17 þ 0.18 0.84 þ 0.11 0.56 þ 0.10 0.002
R429Q 0.99 þ 0.30 0.83 þ 0.21 0.82 þ 0.19 0.15
P453A 0.50 þ 0.09 0.40 þ 0.07 0.31 þ 0.04 0.005
P453T 0.36 þ 0.09 0.33 þ 0.05 0.27 þ 0.07 0.21 þ 0.05 0.005
E457A 1.00 þ 0.12 0.90 þ 0.15 0.72 þ 0.22 0.03
Values are given as the mean þ S.D. (wt n = 4; R429Q n = 4; P453A n = 4; P453T n = 6; E457A n = 4).
FEBS 21918 26-4-99
H.C. van Beeren et al./FEBS Letters 450 (1999) 35^3836
receptors. In the case of mutant R429Q, DEA decreased MBC
in a dose-dependent manner, but the observed decrease in Ka
did not reach statistical signi¢cance. After plotting the data in
a double reciprocal plot (Langmuir plot), it was however clear
that DEA is a non-competitive inhibitor for T3 binding to this
mutant as well (Fig. 3).
4. Discussion
Whereas amiodarone itself has almost no inhibitory e¡ect
on the binding of T3 to its nuclear receptors, the major me-
tabolite DEA does inhibit the binding of T3 [4,5]. The results
of the present study indicate that some mutations in the lig-
and binding domain of human TRL1 change the potency of
DEA to inhibit T3 binding to the thyroid hormone receptor.
Whereas no change in inhibitory potency was observed for the
naturally occurring mutants P453A and P453T relative to wild
type TRL1, a stronger inhibitory potency of DEA was ob-
served for the mutant TRL1s R429Q and E457A. This di¡er-
ential behavior of mutant TRL1 with respect to the antago-
nistic (inhibitory) e¡ect of DEA allows us to postulate a
putative location of the DEA binding site in the ligand bind-
ing domain of TRL1.
The amino acid sequences of the hormone binding domain
of the rat TRK1 and the human TRL1 show 88% identity and
are identical from the start of helix 11 (H362 in rTRK1 and
H416 in hTRL1), except for the last three amino acids of
rTRK1 which are lacking in hTRL1 (Fig. 4). It is assumed
that the three-dimensional structure of the hormone binding
domain of rTRK1 and hTRL1 is comparable [12]. Therefore
the position of amino acids R429, P453 and E457 in hTRL1
re£ects the position of R375, P399 and E403 in rTRK1 (Fig.
4).
Inhibition of T3 binding by DEA was non-competitive in
nature for the wild type and all four mutant TRL1s tested,
indicating that the DEA binding site on the receptor is not
equivalent to the T3 binding site of TRL1. The hormone ap-
pears to ¢t tightly in the binding pocket, and is completely
buried inside the receptor molecule [12]. Its ¢t is such that
there is no apparent extra room inside the binding pocket.
This, combined with the fact that DEA is larger and that its
ring structures are not perpendicular, supports the notion that
the DEA binding site may be di¡erent from that of T3.
Fig. 2. Scatchard analyses of the binding of T3 to wild type and human mutant TRL1 in the absence (a) or presence of DEA 10 WM (b),
25 WM (E) or 50 WM (F).
Fig. 3. Langmuir plot of the binding of T3 to mutant TRL1 R429Q
in the absence (a) or presence (b and E) of DEA, constructed from
the data obtained in the Scatchard analysis.
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The results with mutant hTRL1 presented in this paper
permit a more precise delineation of the DEA binding site.
Amino acid P453 is situated at the beginning of the amphi-
pathic helix 12 in a hydrophobic region at the outer surface of
the receptor protein. The change from proline to threonine
(P453T) or from proline to alanine (P453A), although de-
creasing T3 binding (Table 2), does not grossly a¡ect the
hydrophobicity on the outside of the TRL1. The structure of
the protein could di¡er, however, because proline is thought
to be important in angle formation. There is no in£uence of
these mutations on the a⁄nity for DEA, suggesting that it
may not be the precise receptor structure that is important
for DEA binding but its surface hydrophobicity.
Amino acid E457 is a negatively charged spot within a
hydrophobic surface facing outward into the solvent [12]. Mu-
tant E457A, which may be de¢cient in coactivator interaction
[13], gives a change from negatively charged glutamate to
hydrophobic alanine, resulting in an increased inhibitory po-
tency of DEA. This again is compatible with a greater a⁄nity
of DEA for a more hydrophobic outer surface of the TRL1.
To further prove that hydrophobicity is important in DEA
binding, 9th heptad [14] mutant L421R, also facing outward
into the solvent, was tested. A decrease in inhibitory potency
of DEA for this mutant was expected on the basis of the
change from the hydrophobic amino acid leucine to the pos-
itively charged arginine. Unfortunately the initial binding of
T3 was too low to determine the IC50 values of DEA for this
mutant hTRL1 and perform the other experiments.
In our study the ligand binding a⁄nity of mutant R429Q
was not a¡ected but the inhibitory potency of DEA was al-
most two times higher compared to wild type (IC50 32 WM vs.
56 WM). Despite the normal ligand binding a⁄nity and coac-
tivator recruitment [15] the RTH mutant R429Q [16,17] is
impaired in corepressor release giving rise to increased nega-
tive transcription regulation [15]. The arginine residue 429
(TRL1) participates in a hydrophilic interaction with the
charged pair arginine 383 (TRL1) and glutamic acid 311
(TRL1) forming a polar invagination [15]. We recently argued
that (part of) the mechanism of action of DEA could be an
increase in corepressor binding by the TR [18]. An interesting
parallel is therefore present between the supposed mechanisms
of action behind R429Q and DEA.
In conclusion, these ¢ndings lead us to postulate that amino
acids R429 and E457 are at or close to the binding site for
DEA. This putative DEA binding site on hTRL1 thus di¡ers
from the T3 binding site, in accordance with the non-compet-
itive nature of the inhibition of T3 binding to TRL1 by DEA.
The involvement of amino acids R429 and E457 in cofactor
binding [13,15] combined with their apparent role in DEA
binding (this study) may help to clarify the mechanism of
action of the drug amiodarone.
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